ImpriMed Raises $10M Series A2 for Precision Oncology

ImpriMed spent nine years building a commercial oncology dataset in a market that moves faster than human medicine. Its $10M Series A2 bridge will test whether that veterinary operating history can survive the regulatory, clinical, and commercial crossing into human cancer care.

LB Investment led the round. New investors NAVER D2SF, Samsung Securities, and Alois Ventures joined returning investors BonAngels and Han River Partners, according to the official September 18 announcement. The financing follows ImpriMed's $23M Series A in 2023.

The round arrives as functional precision medicine is moving from a persuasive scientific idea toward a harder institutional test. Measuring how a patient's living cancer cells respond to drugs can reveal information that genomic signals alone may miss, but clinical adoption still depends on standardized assays, regulatory clearance, laboratory certification, prospective evidence, and a workflow physicians can actually use.

What ImpriMed Raised and Who Backed It

ImpriMed's $10M financing is described as a Series A2 bridge rather than a new priced Series B. LB Investment led the round, while NAVER D2SF, Samsung Securities, and Alois Ventures invested as new backers. BonAngels and Han River Partners returned, giving the round a mix of fresh strategic reach and existing investor conviction.

The company did not disclose a valuation, ownership terms, revenue, margins, or individual check sizes. ImpriMed's two latest official funding announcements account for $33M, including the $23M Series A led by SBVA, but older funding databases disagree on the company's cumulative total. The honest number is therefore the one the primary record can support, not the most impressive figure a database can assemble.

The bridge is intended to support U.S. commercialization and expansion into Asia and other international markets. ImpriMed is targeting FDA clearance and CLIA certification by Q1 2027 for initial human products, making this round less about proving that live-cell testing is interesting and more about proving that it can survive regulation, quality systems, clinical integration, and commercial scrutiny.

From Veterinary Oncology to Human Cancer Care

Co-founders Sungwon Lim, CEO, and Jamin Koo, CTO, started ImpriMed in 2017 after studying at KAIST and Stanford. The company first commercialized its platform in veterinary oncology, where treatment cycles move faster and clinical outcomes can accumulate more quickly than in human oncology.

ImpriMed now reports more than 27,000 canine and feline lymphoma tests across more than 600 hospitals in the United States, Canada, the United Kingdom, France, and South Korea. Those figures are company-reported, but they describe something strategically useful: years of laboratory operations, clinician feedback, sample handling, and real-world outcome collection rather than a model trained only on a static research dataset.

The evidence still needs careful accounting. A peer-reviewed retrospective study in relapsed canine B-cell lymphoma associated treatment aligned with ImpriMed's predictions with better response and survival outcomes. That supports the veterinary case; it does not establish human clinical benefit, and ImpriMed states that its U.S. human predictions remain for research and investigational use only.

How the xCellSense Platform Works

ImpriMed's xCellSense platform keeps patient-derived cancer cells viable outside the body and measures how they respond to candidate drugs. The company then combines those functional results with genomic, immunophenotypic, clinical, and real-world outcome data to produce treatment-response analysis.

For acute myeloid leukemia and acute lymphoblastic leukemia research, ImpriMed says xCellSense can evaluate responses across as many as 21 chemotherapeutic agents and return results within 7 days. The company reports that its broader model-development work draws on more than 3.5M data points. Those capabilities matter because cancer treatment is often decided under time pressure, while the patient in front of the clinician may not behave like the average patient in a trial or database.

ImpriMed is also expanding its contract research organization work for biopharma teams. Live-cell drug-response analysis can support compound evaluation, combination testing, patient stratification, and the search for biological signals that conventional molecular profiling may not reveal on its own.

Why Functional Precision Medicine Matters Now

The National Cancer Institute has made functional precision medicine a visible part of its current oncology agenda. NCI Director Anthony Letai argues that testing therapies directly on living patient cancer cells can complement genomic precision medicine, especially when mutations do not point clearly to an effective treatment.

NCI also identifies the field's difficult unfinished work. Living tissue must be collected and handled differently from samples preserved for ordinary pathology. Assays need standards, clinical studies must show that the information improves outcomes, and regulators, laboratories, insurers, pathologists, and oncologists all need enough confidence to incorporate the results into care.

That institutional agenda makes ImpriMed's timing unusually relevant. The company is entering human oncology with veterinary operating history, a growing functional dataset, and commercial experience, but it still has to produce the human evidence and regulatory credibility that the market requires. Veterinary scale is an asset in that crossing, not a substitute for completing it.

What the $10M Must Accomplish

ImpriMed says it is developing products for blood cancers and blood infection, pursuing FDA clearance and CLIA certification, building partnerships with major U.S. hospitals, and expanding across North America, Asia, and Europe. In South Korea, the company says its multiple-myeloma prognosis and therapy-response software has received Innovative Medical Device designation from the Ministry of Food and Drug Safety and is progressing through approval and commercialization.

The company has not named the U.S. hospital partners in its financing announcement, and its Q1 2027 regulatory timeline remains a target. Those gaps do not invalidate the story; they define the work investors are financing. ImpriMed must turn a platform with strong veterinary usage into a human product that can produce reproducible evidence, meet laboratory and device requirements, and earn the trust of clinicians who cannot treat an algorithm's confidence score as a clinical outcome.

The Signal Beyond the Round

ImpriMed's bridge reflects a broader shift in precision oncology from reading tumors only as molecular code toward observing how living cells behave under treatment pressure. The useful future is likely additive: genomics, functional response, immunophenotyping, clinical history, and outcomes working together rather than one data type claiming the whole patient.

ImpriMed has spent nine years collecting the operating memory that comes from real samples and treatment decisions. The next phase will be judged by a narrower and more demanding audience: regulators, laboratory inspectors, hospital partners, and clinicians deciding whether the platform adds enough evidence to change care. The $10M gives the company room to make that case; the clinical handoff will decide whether the evidence travels.